Deamidation and isomerization liability analysis of 131 clinical-stage antibodies

Contemporary in vivo and in vitro discovery platform technologies greatly increase the odds of identifying high-affinity monoclonal antibodies (mAbs) towards essentially any desired biologically relevant epitope. Lagging discovery throughput is the ability to select for highly developable mAbs with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Lu, Xiaojun, Nobrega, R. Paul, Lynaugh, Heather, Jain, Tushar, Barlow, Kyle, Boland, Todd, Sivasubramanian, Arvind, Vásquez, Maximiliano, Xu, Yingda
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6343770/
https://ncbi.nlm.nih.gov/pubmed/30526254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1548233
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados